These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 28411715)

  • 1. Proposal for a national coverage determination for the treatment of varicose veins and venous disease due to disparate Centers for Medicare and Medicaid Services local coverage determination policies.
    Welch HJ; Kabnick L; Vasquez MA; Monahan DL; Lurie F; Jacobowitz G
    J Vasc Surg Venous Lymphat Disord; 2017 May; 5(3):453-459. PubMed ID: 28411715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Private payers' varicose vein policies are inaccurate, disparate, and not evidence based, which mandates a proposal for a reasonable and responsible policy for the treatment of venous disease.
    Welch HJ; Schul MW; Monahan DL; Iafrati MD;
    J Vasc Surg Venous Lymphat Disord; 2021 May; 9(3):820-832. PubMed ID: 33684590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value-based interventional pain management: a review of medicare national and local coverage determination policies.
    Manchikanti L; Falco FJ; Benyamin RM; Helm S; Singh V; Hirsch JA
    Pain Physician; 2013; 16(3):E145-80. PubMed ID: 23703416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health services utilization in the U.S. population by health insurance coverage.
    Garfinkel SA; Corder LS
    Natl Med Care Util Expend Surv B; 1986 Dec; (13):1-38. PubMed ID: 10304187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) meeting in July 2016 on chronic venous disease: An important first step.
    Lawrence PF
    J Vasc Surg Venous Lymphat Disord; 2017 May; 5(3):301-302. PubMed ID: 28411693
    [No Abstract]   [Full Text] [Related]  

  • 6. Report of the Society for Vascular Surgery and the American Venous Forum on the July 20, 2016 meeting of the Medicare Evidence Development and Coverage Advisory Committee panel on lower extremity chronic venous disease.
    Gloviczki P; Dalsing MC; Henke P; Lal BK; O'Donnell TF; Shortell CK; Huang Y; Markovic J; Wakefield TW
    J Vasc Surg Venous Lymphat Disord; 2017 May; 5(3):378-398. PubMed ID: 28411706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inequalities of health insurance guidelines for the treatment of symptomatic varicose veins.
    Schul MW; King T; Kabnick LS
    Phlebology; 2014 May; 29(4):236-46. PubMed ID: 23559591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Focus on locus: evolution of Medicare's local coverage policy.
    Foote SB
    Health Aff (Millwood); 2003; 22(4):137-46. PubMed ID: 12889761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local medical review policies.
    Bryant N
    Issue Brief Cent Medicare Educ; 2004; 5(1):1-6. PubMed ID: 15002463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning?
    Phillips KA
    JAMA; 2018 Jun; 319(23):2379-2380. PubMed ID: 29710095
    [No Abstract]   [Full Text] [Related]  

  • 11. Federal and Statewide Coverage for Opioid-Sparing Chronic Pain Treatments.
    McKay M; Gorvine MM; Zaller N; Singh V; Goree J
    Pain Physician; 2022 Dec; 25(9):E1457-E1466. PubMed ID: 36608017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Supplemental health insurance coverage among aged Medicare beneficiaries.
    Garfinkel SA; Corder LS
    Natl Med Care Util Expend Surv B; 1985 Aug; (5):1-37. PubMed ID: 10304189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparing for the outpatient treatment of venous disease under MACRA.
    Leers SA; Woo K; Rathbun J; Johnson B
    J Vasc Surg Venous Lymphat Disord; 2018 Jan; 6(1):133. PubMed ID: 29248103
    [No Abstract]   [Full Text] [Related]  

  • 14. CHANGING FACE OF MEDICARE'S NATIONAL COVERAGE DETERMINATIONS FOR TECHNOLOGY.
    Chambers JD; Chenoweth MD; Pyo J; Cangelosi MJ; Neumann PJ
    Int J Technol Assess Health Care; 2015 Jan; 31(5):347-54. PubMed ID: 26750558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coverage of Nonpharmacologic Treatments for Low Back Pain Among US Public and Private Insurers.
    Heyward J; Jones CM; Compton WM; Lin DH; Losby JL; Murimi IB; Baldwin GT; Ballreich JM; Thomas DA; Bicket MC; Porter L; Tierce JC; Alexander GC
    JAMA Netw Open; 2018 Oct; 1(6):e183044. PubMed ID: 30646222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does MFD fit under Medicare coverage?
    Robers S
    Nephrol News Issues; 2001 May; 15(6):52-3, 55. PubMed ID: 12109003
    [No Abstract]   [Full Text] [Related]  

  • 17. Private payers disagree with Medicare over medical device coverage about half the time.
    Chambers JD; Chenoweth M; Thorat T; Neumann PJ
    Health Aff (Millwood); 2015 Aug; 34(8):1376-82. PubMed ID: 26240252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laboratory services regulations carry HIM implications.
    Prophet S
    J AHIMA; 2002 Sep; 73(8):20-2, 24. PubMed ID: 12233203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Roadmap for Improving Medicare's Application of Coverage With Evidence Development.
    Lakdawalla D; Tunis S; Neumann P; Whicher D; Zeitler E; Liden B
    Value Health; 2024 Sep; 27(9):1191-1195. PubMed ID: 38795958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variation in Medicaid and commercial payer coverage of aducanumab for Alzheimer's disease.
    Lin PJ; Levine A; Rucker J; Chambers JD
    Alzheimers Dement; 2023 Aug; 19(8):3654-3669. PubMed ID: 36852834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.